04:47 PM EDT, 03/13/2026 (MT Newswires) -- Hydreight Technologies ( HYDTF ) said after trade Friday it has completed a $300,000 strategic investment in Insu Therapeutics, buying 800,000 units at $0.375 each.

The news came out after shares in NURS had gained near 6% during the regular session.

Hydreight ( HYDTF ) said its investment reflects the company's strategy of exploring innovations that may enhance the capabilities of its national pharmacy and telehealth infrastructure. Hydreight ( HYDTF ) added it continues to expand its national pharmacy network and platform licensee ecosystem, and the company believes innovations in therapeutic delivery could further support the growing range of treatments being offered through its infrastructure.

Under the terms of a subscription agreement, each unit involved includes one Insu common share and one warrant, with each warrant allowing the holder to buy another share at $1 within two years. The investment was paid half in cash and half in Hydreight ( HYDTF ) shares, the company added.

Insu Therapeutics is developing a buccal drug delivery platform that allows certain US Food and Drug Administration-approved peptide drugs to be absorbed through the oral mucosa rather than via injection or gastrointestinal oral delivery. Insu has completed animal studies for insulin and is now running similar studies for Ozempic (semaglutide). It aims to submit an application to the FDA for clinical trial approval in early 2027, according to the statement.